These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 9162907)

  • 21. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease.
    Hautzel H; Pisar E; Yazdan-Doust N; Schott M; Beu M; Müller HW
    J Nucl Med; 2010 Dec; 51(12):1917-22. PubMed ID: 21078788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy?
    Gotthardt M; Rubner C; Bauhofer A; Berce F; Oyen WJ; Goecke J; Pfestroff A; Schlieck A; Corstens FH; Béhé M; Behr TM
    Nuklearmedizin; 2006; 45(5):206-12. PubMed ID: 17043731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The effective half-life of 131I during the treatment of autonomous thyroid disease with radioiodine].
    Müller B; Bares R; Büll U
    Nuklearmedizin; 1991 Jun; 30(3):71-6. PubMed ID: 1714566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
    Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
    Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of thyrotoxicosis in children and adolescents: 35 years' experience in 304 patients.
    Azizi F; Amouzegar A
    J Pediatr Endocrinol Metab; 2018 Jan; 31(2):159-165. PubMed ID: 29306930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
    Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
    Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies of radioiodine therapy for Graves' disease.
    Lind P
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioiodine therapy of thyroid autonomy.
    Reiners C; Schneider P
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S471-8. PubMed ID: 12192548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?
    Schneider P; Körber C; Körber-Hafner N; Hänscheid H; Reiners C
    Nuklearmedizin; 2002 Dec; 41(6):240-4. PubMed ID: 12520660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs.
    Koornstra JJ; Kerstens MN; Hoving J; Visscher KJ; Schade JH; Gort HB; Leemhuis MP
    Neth J Med; 1999 Nov; 55(5):215-21. PubMed ID: 10593131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
    Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
    Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The surgical treatment of Graves' disease].
    de Ruijter SH; van Dalen T; Muller AF
    Ned Tijdschr Geneeskd; 2006 Jun; 150(24):1321-5. PubMed ID: 16808361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
    Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
    Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyrotoxicosis in Sierra Leone: diagnosis and treatment with radioactive iodine (131I).
    Knox-Macaulay HH
    Trop Geogr Med; 1982 Jun; 34(2):169-75. PubMed ID: 7123649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Predictors of the efficacy of radioiodine therapy of Graves' disease in children and adolescents].
    Rumyantsev PO; Saenko VA; Dzeytova DS; Trukhin AA; Sheremeta MS; Slashchuk KY; Degtyarev MV; Serzhenko SS; Yasuchenia VS; Zakharova SM; Sirota YI
    Probl Endokrinol (Mosk); 2020 Oct; 66(4):68-76. PubMed ID: 33351361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonimmunogenic hyperthyroidism: cumulative hypothyroidism incidence after radioiodine and surgical treatment.
    Kinser JA; Roesler H; Furrer T; Grütter D; Zimmermann H
    J Nucl Med; 1989 Dec; 30(12):1960-5. PubMed ID: 2585096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.